Monogram Presents Results of First eTag Breast Cancer Studies
May 31 2007 - 8:00AM
PR Newswire (US)
Clinical data utilizing Monogram's eTag(TM) technology featured in
presentations at American Society of Clinical Oncology's (ASCO)
43rd Annual Meeting SOUTH SAN FRANCISCO, Calif., May 31
/PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM)
today announced that two presentations detailing initial studies on
the clinical utility of its proprietary eTag technology in
metastatic breast cancer will be presented at the 43rd American
Society of Clinical Oncology (ASCO) meeting (June 1-5) in Chicago,
Illinois. A third presentation will describe the molecular
characterization of cell lines that have acquired resistance to the
breast cancer drug Herceptin (trastuzumab). Currently under
development, the eTag technology is a highly advanced diagnostic
platform for quantifying protein expression, protein-protein
interactions (e.g. receptor dimerization) and protein modification
(e.g. phosphorylation). This unique capability enables the eTag
technology to accurately assess signaling pathways that control
cell growth, proliferation and survival. Dysregulation of these
pathways has been associated with a wide variety of tumors,
including breast, lung, prostate and colorectal cancers. Many new
therapeutic candidates target various steps in these critical cell
signaling pathways, potentially providing an opportunity for the
diagnostic capabilities of the eTag technology to improve patient
treatment and drug development. The presentations at the ASCO
meeting describe the Company's progress in addressing two critical
questions related to the treatment of HER2(+) breast cancer
patients. First, why don't all HER2(+) breast cancers respond
equally well to targeted therapy with Herceptin. And second, why do
many HER2(+) breast cancers develop resistance to Herceptin
treatment. The presentations are: - "Differential survival
following trastuzumab treatment based on quantitative HER2
expression and HER2-HER2 dimerization in a clinic- based cohort of
patients with metastatic breast cancer." (Poster 12 / Abstract
1025, presented Saturday, June 2, 8:00 a.m. - 12:00 p.m., Room
S403) - "HER2 expression and HER2-HER2 dimerization identifies
subpopulations of metastatic breast cancer patients with different
probabilities of long- term survival following trastuzumab
treatment and with different requirements for concomitant
chemotherapy" (Poster JJ5, Abstract 10557, presented Sunday, June
3, 8:00 a.m. - 12:00 p.m., S Hall A2) - Patterns of HER-family
receptor dimerization in trastuzumab susceptible and trastuzumab
resistant cell lines (Poster A3, Abstract 2533, presented Sunday,
June 3, 8:00 a.m. - 12:00 p.m., S Hall A2) "The eTag platform
represents a powerful new tool for advancing personalized medicine
in cancer treatment," said Monogram CEO Bill Young. "By providing
quantitative measurements to characterize disease at the molecular
level and by detecting the protein complexes to help accurately
predict an individual patient's response to specific therapies,
eTag technology may empower oncologists with the critical
information needed to improve patients' lives and may help drive
the development of more effective targeted cancer therapies." About
the eTag System Monogram's eTag assays enable detailed analysis of
protein drug targets and signaling pathways in cancer cells, using
tissue lysates or FFPE specimens, which is the standard format in
most pathology labs. The assays can provide information on a drug's
mechanism of action, selectivity and potency in a biological
setting in pre-clinical research, and enable selection of clinical
trial populations later in a drug's development. In addition,
Monogram believes these assays may ultimately be used to help
physicians better determine whether certain therapies are more
appropriate for individual cancer patients, and whether to combine
therapies with different mechanisms or properties. The first
commercially available activated receptor test panel based on eTag
technology will be focused on the EGFR/HER receptor family. About
Monogram Biosciences, Inc. Monogram is advancing individualized
medicine by discovering, developing and marketing innovative
products to guide and improve treatment of serious infectious
diseases and cancer. The Company's products are designed to help
doctors optimize treatment regimens for their patients that lead to
better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new
and improved antiviral therapeutics and vaccines as well as
targeted cancer therapeutics. More information about the Company
and its technology can be found on its web site at
http://www.monogrambio.com/. Forward Looking Statements Certain
statements in this press release are forward-looking, including
statements regarding the ability of assays based on the eTag
technology to predict individual patient response to targeted
cancer therapies. These forward-looking statements are subject to
risks and uncertainties and other factors, which may cause actual
results to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks and
uncertainties relating to the performance of our products; whether
measurement of dimerization or protein pathway activation are key
indicators in determining individual patient response; our ability
to obtain additional cohorts of patient samples for additional
studies, our ability to successfully conduct clinical studies and
the results obtained from those studies; whether larger
confirmatory clinical studies will confirm the results of initial
studies; whether the results of studies conducted with patient
samples treated with a particular targeted cancer therapy will be
representative of results with other targeted therapies; whether
clinical data derived from these studies will be adequate to
support the commercial introduction of a test for patient
responsiveness to targeted cancer therapies; the timing and launch
of eTag assays for patient use; our ability to establish reliable,
high-volume operations at commercially reasonable costs; the
development of competitive technologies; actual market acceptance
of our products and adoption of our technological approach and
products by pharmaceutical and biotechnology companies; our
estimate of the size of our markets; our estimates of the levels of
demand for our products; the timing and ultimate size of
pharmaceutical company clinical trials; whether payors will
authorize reimbursement for its products; whether the FDA or any
other agency will decide to regulate Monogram's products or
services; whether the draft guidance on Multivariate Index Assays
recently issued by FDA applies to our current or planned products;
the ultimate validity and enforceability of our patent applications
and patents; the possible infringement of the intellectual property
of others; whether licenses to third party technology will be
available; and whether Monogram is able to build brand loyalty and
expand revenues.. For a discussion of other factors that may cause
Monogram's actual events to differ from those projected, please
refer to the Company's most recent annual report on Form 10-K and
quarterly reports on Form 10-Q, as well as other subsequent filings
with the Securities and Exchange Commission. We do not undertake,
and specifically disclaim any obligation, to revise any
forward-looking statements to reflect the occurrence of anticipated
or unanticipated events or circumstances after the date of such
statements. eTag is a trademark of Monogram Biosciences, Inc.
Herceptin is a trademark of Genentech, Inc. contacts: Alfred G.
Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean
Healthcare Tel: 650 624-4576 Tel: 415 677-2700 DATASOURCE: Monogram
Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial
Officer, +1-650-624- 4576, ; Jeremiah Hall, Feinstein Kean
Healthcare, +1-415-677-2700, Web site: http://www.monogrambio.com/
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Aug 2023 to Aug 2024